SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.
Amyl Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for various forms of amyloidosis. The company utilizes a novel mechanism to bind to the amyloid folds of toxic protein aggregates, including antibody light chain (AL) and transthyretin (TTR) aggregates, which contribute to systemic amyloidosis. Additionally, Amyl Therapeutics targets amyloid-β (Aβ), Tau, and α-synuclein aggregates associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By addressing multiple misfolded proteins responsible for both peripheral and central nervous system pathologies, the company aims to provide effective therapies that can prevent the accumulation of harmful protein aggregates in organs and the brain, offering new treatment options for patients suffering from these debilitating conditions.
keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.
Keranova S.A. is a French start-up established in 2015, specializing in the design and development of surgical equipment for ophthalmologic applications, specifically targeting the anterior segment of the eye. Headquartered in Saint Etienne, with an additional office in Vénissieux, the company focuses on creating innovative medical technologies. Keranova's teams are dedicated to advancing ophthalmic procedures through the development of novel surgical instruments that incorporate a unique patented technology, marking significant improvements in the effectiveness and efficiency of eye surgeries.
Private Equity Round in 2019
Doc Generici s.r.l. is a pharmaceutical company based in Milan, Italy, specializing in the production and distribution of generic medicines. Founded in 1996, the company emerged following the enactment of legislation that facilitated the use of equivalent medicines in Italy. It offers a diverse range of therapeutic products, including anti-infective, anti-neoplastic, cardiovascular, dermatological, hematological, gastrointestinal, neurological, ophthalmological, respiratory, musculoskeletal, and genitourinary medications. Additionally, Doc Generici provides systemic hormonal preparations, nutritional supplements, and medical devices. The company aims to deliver effective and affordable treatment options for various medical conditions, ensuring accessibility for patients through its broad product portfolio. As a subsidiary of Diocle S.p.A., Doc Generici maintains its operational independence while focusing on high-quality manufacturing practices and effective communication within the healthcare sector.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Omnipharm, is a supplier of natural ingredients made in France
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Private Equity Round in 2018
Biobest N.V. is a company that develops and supplies natural crop care systems, focusing on bumblebee pollination and sustainable crop management. It offers a range of products, including biological pollination solutions like bumblebees, biological control products such as beneficial insects, mites, nematodes, and biopesticides. Additionally, Biobest provides monitoring and scouting tools, including sticky traps, pheromone traps, and lures, designed to assist growers in managing pests. The company also supplies various supporting products, including food supplements for predatory bugs, nutritional supplements based on pollen, foliar fertilizers, and tools for pest detection. Founded in 1987 and based in Westerlo, Belgium, Biobest operates through distributors both domestically and internationally, supported by a network of subsidiaries and production sites. The company is dedicated to providing technical advisory and support services to enhance crop care practices.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Stiplastics S.A.S. engages in designing, developing, and manufacturing medical devices for the healthcare industry
Laboratoires INELDEA, based in Carros, France, specializes in the formulation, development, manufacture, and marketing of a wide range of nutritional and healthcare products. Founded in 2003, the company offers over 400 product references, including food supplements, nutraceuticals, health foods, and organic cosmetics. With a focus on natural ingredients and innovative formulations, INELDEA addresses the specific health needs of diverse demographics, including children, athletes, and adults. The company distributes its products through pharmacies, drugstores, specialty stores, and health professionals, both domestically and internationally. INELDEA is recognized for its commitment to quality and consistency, earning the trust of healthcare professionals and consumers alike.
PhysioAssist, founded in 2012, specializes in developing innovative medical devices aimed at treating obstructive respiratory diseases. The company's patented technology modifies the physical properties of mucus, facilitating the mobilization and removal of secretions to enhance airway clearance. This approach provides healthcare professionals and patients with effective solutions for managing bronchial congestion, ultimately improving the quality of life for those suffering from respiratory conditions. The design and ergonomics of PhysioAssist's devices have been carefully optimized to ensure they are suitable for daily use in patient care settings.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.
Ivantis Inc. is dedicated to developing innovative treatments for primary open angle glaucoma, a condition affecting over 60 million people globally. The company has created an intracanalicular scaffold or implantable device designed to alleviate high intraocular pressure in patients, offering a less invasive and more effective therapeutic option. Founded in 2007 and based in Irvine, California, Ivantis also provides a Session Persistence Server, which safeguards telnet task workers against data loss due to network issues and ensures terminal emulation users maintain productivity across various devices and operating systems. As Ivantis advances its glaucoma treatment solutions, it aims to expand its focus to other debilitating ophthalmic diseases. The company primarily serves ophthalmology specialists in the United States, providing its solutions for use in clinical trials.
LNA Sante is a global health player with nearly 70 establishments in France and Belgium. Nursing homes (EHPAD and MRS), Follow-up care and rehabilitation (SSR), Home hospitalization structures (HAD), Health centers, Psychiatric clinic. Our mission is to improve the quality of life for people who are temporarily or permanently vulnerable, in a welcoming and caring environment, suitable for everyone and for all ages. Our commitment "To care and take care" of you or your loved ones daily, patients and residents who are welcomed in our structures in France or in Belgium. A mission and commitment shared by all our teams.
Private Equity Round in 2016
Seqens is a company based in Ecully, France, specializing in pharmaceutical synthesis and specialty chemicals. It provides a wide range of active pharmaceutical ingredients, including aspirin, paracetamol, salicylic acid, and para-aminophenol, among others. In addition to these pharmaceutical products, Seqens also offers specialty chemicals such as soda ash, sodium bicarbonate, phenol, and oxygenated solvents. The company primarily serves various demanding industries, including healthcare, electronics, cosmetics, food, and household cleaners. With its focus on market responsiveness, Seqens delivers customized solutions tailored to the specific needs of its customers.
Keranova S.A. is a French start-up established in 2015, specializing in the design and development of surgical equipment for ophthalmologic applications, specifically targeting the anterior segment of the eye. Headquartered in Saint Etienne, with an additional office in Vénissieux, the company focuses on creating innovative medical technologies. Keranova's teams are dedicated to advancing ophthalmic procedures through the development of novel surgical instruments that incorporate a unique patented technology, marking significant improvements in the effectiveness and efficiency of eye surgeries.
Private Equity Round in 2016
Novacap is a leading manufacturer and distributor of essential chemicals for use in everyday products. We have a very wide range of products among which salicylic acid and aspirin for which we are the worldwide leader, paracetamol and para-aminophenol, soda ash and sodium bicarbonate, phenol and oxygenated solvents, hydrochloric acid and derivatives which are used in growing end-markets such as pharmaceutical & healthcare, food & feed, cosmetics & fragrances, home care and environment. Construction and automotive markets are historical markets for which we are also a reference partner.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
OriGene Technologies, Inc. specializes in the development, manufacturing, and sale of genome-wide research and diagnostic products tailored for academic, pharmaceutical, and biotechnology applications. Founded with a focus on creating a comprehensive collection of full-length human cDNAs, the company offers a diverse range of products, including cDNA clones, shRNA and siRNA tools, and CRISPR/Cas9 genome editing products. Additionally, OriGene provides proteins and lysates, an extensive array of antibodies for immunohistochemistry, and various assay kits, including ELISA and luminex kits. The company supports critical biological research by supplying essential resources for cancer biomarker studies, stem cell research, and other areas. With a commitment to facilitating gene-based research, OriGene distributes its products globally through distributors and online channels. Established in 1995 and based in Rockville, Maryland, OriGene continues to enhance its offerings to meet the evolving needs of researchers in the life sciences field.
keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging, with a focus on enhancing precision medicine for cancer treatment. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments known as minibodies, which are designed for diagnostic imaging using Positron Emission Tomography (PET). ImaginAb's portfolio includes precision imaging products targeting CD8 and CD4 for immune-oncology applications, as well as PSMA PET for prostate cancer diagnostics. By creating highly targeted diagnostic imaging agents that retain the specificity of parental antibodies while being optimized for clinical use, ImaginAb addresses critical needs in patient selection and treatment monitoring for cancer immunotherapy.
Kalila Medical is developing a novel platform of specialized catheters for vascular and intracardiac access. The company’s initial product offering includes a family of steerable sheaths for use during catheter based atrial fibrillation ablation. Compatible with 8Fr and 12Fr ablation catheters, the Kalila sheath provides superior torque and tip control during catheter delivery and lesion formation . Founded in 2010, Kalila Medical is the third of a portfolio of companies to be formed out of Shifamed LLC (www.shifamed.com), a Silicon Valley based medical device incubator. Kalila Medical – Redefining precision and control
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
HumanCharger is a bright light therapy device that has a unique and patented mechanism of action which stimulates the photosensitive proteins on the surface of the brain using a calibrated white light that passes through the ear canals. Using the HumanCharger® for only 12 minutes a day can significantly increase your energy levels, improve mood and increase your mental alertness.
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
Private Equity Round in 2013
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.
Advencis
Private Equity Round in 2012
Advencis is a developer and manufacturer of lab instruments and medical devices.The company has developed Advencis Bio-System Incubator, a modular system of early detection which is fully automated for industrial microbiology (food and pharmaceutical industries) and clinical markets. The system provides highly sensitive detection of the microorganisms on agar plates and on filter-based devices. It also provides Advencis Bio-System Software which is a real time monitoring application.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
QuantaLife, Inc. is a biotechnology startup focused on developing and marketing innovative nucleic acid testing technologies for various sectors, including life science research, clinical diagnostics, and personalized medicine. The company offers advanced genetic analysis platforms designed to facilitate rapid detection and quantification of nucleic acids in complex samples using a flexible, automated instrument. QuantaLife's proprietary testing method significantly enhances performance compared to existing technologies while reducing costs, making it a valuable tool for researchers and clinicians. By providing a cost-effective and high-resolution platform for validating next-generation sequencing discoveries, QuantaLife enables the exploration of complex genetic landscapes, the identification of new disease associations, and the advancement of molecular diagnostic tests.
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.